Unity Biotechnology, Inc.: Nasdaq/NYSE listing notice — Unity Bio receives Nasdaq deficiency notice for stockholders' equity below $10M; may face delisting

Unity Biotechnology, Inc.

Nasdaq notified Unity on March 14, 2025 that stockholders' equity fell below $10M minimum for continued listing (Rule 5450(b)(1)(A)).
Company must submit a compliance plan by April 28, 2025; if accepted, Nasdaq may grant up to 180 days to cure.
Unity expects ASPIRE study 24-week data in Q1 2025 and 36-week data in Q2 2025; cash runway into Q4 2025.
No immediate impact on trading of common stock (UBX); trading continues on Nasdaq Global Select Market.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

Unity Biotechnology, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A), 5450(b)(2), 5450(b)(3)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5450(b)(1)(A), 5450(b)(2), 5450(b)(3)

Exact text from the filing

March 14, 2025, UNITY Biotechnology, Inc. (“Unity” or the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that its stockholders’ equity as reported in its Annual Report on Form 10-K had fallen below the minimum stockholders’ equity requirement of at least $10,000,000 for continued listing on The Nasdaq Global Select Market set forth in Nasdaq Listing Rule 5450(b)(1)(A). The letter further indicated that, as of the date of the letter, the Company did not comply with certain requirements under the alternative standards set forth in Nasdaq Listing Rules

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-25-040260

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.